Also known as: ReoPro; c7E3 Fab Antibody Fragment
Abciximab is a pharmaceutical-grade Active Pharmaceutical Ingredient in the Cardiology / GPIIb-IIIa Receptor Antagonist (Biologic) category. Mediocon Inc supplies high-purity Abciximab API (CAS 143653-53-6) from our GMP-certified facility in Aurangabad, Maharashtra, India. We cater to pharmaceutical manufacturers, formulators, and research organizations worldwide.
Abciximab is primarily associated with: GPIIb/IIIa platelet receptor antagonist for percutaneous coronary intervention. Mediocon's Abciximab meets the highest pharmacopoeial standards and is manufactured under WHO-GMP compliant conditions for consistent quality and purity.
Key Features
Applications & Therapeutic Uses
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Purity (SEC-HPLC) | NLT 95.0% |
| Endotoxin | NMT 5 EU/mg (LAL test) |
| Aggregates | Within validated limits |
| Identity | SDS-PAGE / Peptide Mapping Compliant |
| Sterility | Complies with pharmacopoeia |
| Bioburden | Complies with pharmacopoeia |
| Packing | Cold-chain packaging / single-use vials, as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Abciximab (CAS 143653-53-6) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Abciximab is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (Pharma Grade / Injectable Biologic). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance